By analyzing two independent patient cohorts, we showed and validated for the first time that integrated STMN1 expression, phosphorylation status and known clinicopathological characteristics of cancer patients (shown here for breast cancer) can predict clinical outcomes successfully, and exhibit a remarkable predictive value to guide appropriate treatment. Here, STMN1 is linked to breast cancer.